Halozyme Therapeutics Inc
Changes in Ionis Pharmaceuticals’ Valuation after 1Q17
In 1Q17, Ionis Pharmaceuticals reported EPS (earnings per share) of $0.03 on revenue of $110.3 million, compared with EPS of -$0.52 on revenue of $36.9 million in 1Q16. In this series, we’ll look at its valuation since 1Q17.
Agios Initiates Phase 1b Trial of AG-221 or AG-120: Stock Up 14%
Agios Pharmaceuticals (AGIO) stock rose 14% after it announced the initiation of the Phase 1b trial of either AG-221 or AG-120.
Halozyme Therapeutics gets huge 60% increase in Iridian holdings
Iridian Asset Management now holds 11,625,215 shares of Halozyme Therapeutics Inc. (HALO), a huge 60% increase. The fund has a 9% stake in the company.